 Emmaus Life Sciences Inc OTCQX:EMMA has said the Florida Medicaid Pharmaceutical Therapeutics Committee has approved adding Endari, the companys prescription-grade L-glutamine oral powder for the treatment of sickle cell disease, to the Florida Medicaid Preferred Drug List PDL with effect from April 1, 2022. Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. 